375 related articles for article (PubMed ID: 32521069)
1. A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis.
Shi J; Xu J; Chen Y
Dermatol Ther; 2020 Jul; 33(4):e13802. PubMed ID: 32521069
[TBL] [Abstract][Full Text] [Related]
2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
[TBL] [Abstract][Full Text] [Related]
9. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
10. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
Xu S; Gao X; Deng J; Yang J; Pan F
J Dtsch Dermatol Ges; 2021 Jan; 19(1):47-56. PubMed ID: 33377312
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Stakias V; Puig L
Dermatol Ther (Heidelb); 2022 Jan; 12(1):167-184. PubMed ID: 34862951
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
15. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
Leonardi CL; See K; Burge R; Sun Z; Zhang Y; Mallbris L; Garrelts A; Warren RB
Adv Ther; 2022 May; 39(5):2256-2269. PubMed ID: 35316500
[TBL] [Abstract][Full Text] [Related]
16. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
17. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
19. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
20. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Warren RB; See K; Burge R; Zhang Y; Brnabic A; Gallo G; Garrelts A; Egeberg A
Dermatol Ther (Heidelb); 2020 Feb; 10(1):73-86. PubMed ID: 31686337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]